CD274 and prostate cancer: Increases in farnesyltransferase expression activity have been reported in prostate cancer patients, correlating with poor prognosis [37], and PT-112 has shown some efficacy signals in late-stage mCRPC, either alone [13] or in combination with PD-L1 immune checkpoint inhibition [14].